Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.35 +0.24 (+0.29%)
Streaming Delayed Price Updated: 1:13 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
A Closer Look at Merck & Co's Options Market Dynamics
 
Via Benzinga
Merck & Co Unusual Options Activity For March 10
 
Via Benzinga
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
Inflation Isn’t Going Away, But These Sectors Don’t Care
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding. 
Via Talk Markets
Topics ETFs Economy Stocks / Equities
How Do Investors Really Feel About Merck & Co?
 
Via Benzinga
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025. 
Via Benzinga
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
From Merck & Co., Inc.
Via Business Wire
Merck Injects $1 Billion To Expand Vaccine Production In US
Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments. 
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains. 
Via MarketBeat
Merck Unveils New Facility to Increase Vaccine Production Capacity
From Merck & Co., Inc.
Via Business Wire
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Institutional Investors Bet $1B on These 4 Stocks—Should You?
Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well? 
Via MarketBeat
3 Magnificent S&P 500 Dividend Stocks Down 20% to 63% to Buy and Hold Forever
Great investments are even better and more fruitful when you can buy them at a discount. 
Via The Motley Fool
Topics Stocks
5 Top Stocks to Buy for March
These 5 stocks look rather intriguing at current levels. 
Via The Motley Fool
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S.... 
Via Benzinga
Topics Government World Trade
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys. 
Via MarketBeat
Topics Stocks
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.